Last $1.12 USD
Change Today 0.00 / 0.00%
Volume 3.1K
ULUR On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 10:04 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

4452 Beltway Drive

Addison, TX 75001

United States

Phone: 214-905-5145

Fax: 214-905-5130

ULURU Inc., a specialty pharmaceutical company, engages in developing and commercializing a range of wound care and mucoadhesive film products based on its patented Nanoflex and OraDisc drug delivery technologies, with the goal of improving outcomes for patients, health care professionals, and health care payers. Marketed Products The company has used its drug delivery technology platforms to develop the following products and product candidates: Altrazeal Altrazeal Transforming Powder Dressing, based on the company’s Nanoflex technology, has the potential to change the way health care providers approach their treatment of wounds. The product is indicated for exuding wounds, such as partial thickness burns, donor sites, abrasions, surgical, trauma, and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The powder fills and seals the wound to provide an optimal moist wound healing environment. The wound exudate is controlled through the high moisture vapor transpiration rate (MVTR) of the material generated by capillary forces that creates a low pressure environment at the wound bed, which supports cellular function and tissue repair and holds the dressing in place. The focus of the company’s commercial activities is introducing Altrazeal in all major international markets, in conjunction with its European partners, through its 25% owned company, Altrazeal Trading Ltd. Altrazeal is already marketed in Australia and Austria. The company has a licensing and supply agreement with Jiangxi Aiqilin Pharmaceuticals Group Company, a corporation in China (Aiqilin), for the development and commercialization of Altrazeal in China, including Hong Kong, Macau, and Taiwan. The agreement covers Altrazeal, Altrazeal Silver, and Altrazeal Collagen. In 2012, the company executed a license and supply agreement with Melmed Holding AG (Melmed) to market Altrazeal throughout the European Union, Australia, New Zealand, North Africa, and the Middle East. Aphthasol (Amlexanox 5% Paste) Aphthasol, amlexanox 5% paste, is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of canker sores. Marketing authorization for amlexanox 5% paste in the United Kingdom is received. Approval to market its granted in Austria, Germany, Greece, Finland, Ireland, Luxembourg, the Netherlands, Norway, Portugal, and Sweden. The therapeutic Products Programme, the Canadian equivalent of the FDA, has issued a notice of compliance permitting the sale of amlexanox 5% paste, called Apthera, in Canada by Pharmascience Inc., the company’s Canadian partner. In addition to the company’s license agreement with Meda AB, licensing agreements have been executed with Laboratories Esteve for Spain, Portugal and Greece; Pharmascience Inc. for Canada; EpiTan, Ltd. for Australia and New Zealand; Orient Europharma, Co., Ltd for Taiwan, Hong-Kong, the Philippines, Thailand, and Singapore; and KunWha Pharmaceutical Co., LTD for South Korea. Contract Pharmaceuticals Ltd. Canada is the company’s contract manufacturer for all markets, including the United States. OraDisc A The company has developed an adhesive film product that is bioerodible. This technology, known as OraDisc, comprises a multi-layered film having an adhesive layer, an optional pre-formed film layer, and a coated backing layer. OraDisc A is developed as a drug delivery system to treat canker sores using the same active ingredient (amlexanox) that is used in Aphthasol paste. OraDisc A is approved by the FDA. The company has a licensing and supply agreement with KunWha Pharmaceutical Co., Ltd for OraDisc A and Aphthasol (5% amlexanox) paste in South Korea. OraDisc B A second mucoadhesive disc product has also been developed for the treatment and management of oral pain. This product contains 15 milligrams of benzocaine, which is the maximum allowable strength that falls under the classification of an OTC monograph product. In 2012, the company executed a license and supply agreement with ORADISC GmbH to market worldwide all applications of its OraDisc erodible film technology for dental applications, incl

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULUR:US $1.12 USD 0.00

ULUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.79 USD -0.3401
Smith & Nephew PLC 1,057 GBp -9.00
View Industry Companies
 

Industry Analysis

ULUR

Industry Average

Valuation ULUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 64.7x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 70.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ULURU INC, please visit www.uluruinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.